These early data suggest the need for further in vitro/in vivo studies to unveil the underlying molecular mechanisms, and that Bcl-2 expression and BH3-mimetics response depend on T-ALL genetics and immunophenotype, meaning that they could be exploited as biomarkers for therapy. This evidence concerns the gene BCL2 and acute lymphoblastic leukemia.